Related Experiment Videos
[Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil]
U Sixdorf1, H Bauer, E Märker-Hermann
1Klinik Innere Medizin IV (SP Rheumatologie, Klinische Immunologie und Nephrologie), HSK Dr. Horst Schmidt Klinik GmbH.
History And Admission Findings:
A now 34-year old female patient with long-standing systemic lupus erythematosus (SLE) had successfully been treated with mycophenolate mofetil (MMF) because of former pleuropericardial and pulmonal lupus manifestations when she was admitted with edema for the first time.
Investigations:
Laboratory investigations of urine and blood showed findings compatible with lupus nephritis. Kidney biopsy revealed lupus nephritis type IV.
Treatment And Course:
Despite the initiation of cyclophosphamide bolus and corticosteroid therapy, the kidney function and renal hypertension worsened and the patient developed cerebral manifestations. Finally, synchronization of plasmapheresis with subsequent pulse cyclophosphamide led to remission of SLE.
Conclusion:
Although MMF is a promising innovative agent for induction and maintenance therapy of lupus nephritis that can be used instead of cyclophosphamide, there may be cases like the one reported here, in which MMF cannot prevent lupus flares in first manifestation of severe renal disease.
Related Concept Videos
Cryptococcal Meningitis
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...